{"organizations": [], "uuid": "5f91a1ca0cd0d50bad7ccfcdb7f471bfb0516b9c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glycomimetics-announces-design-of/brief-glycomimetics-announces-design-of-phase-3-clinical-trial-for-gmi-1271-idUSASB0C8U7", "country": "US", "domain_rank": 408, "title": "BRIEF-Glycomimetics Announces Design Of Phase 3 Clinical Trial For GMI-1271", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.772, "site_type": "news", "published": "2018-03-06T05:16:00.000+02:00", "replies_count": 0, "uuid": "5f91a1ca0cd0d50bad7ccfcdb7f471bfb0516b9c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glycomimetics-announces-design-of/brief-glycomimetics-announces-design-of-phase-3-clinical-trial-for-gmi-1271-idUSASB0C8U7", "ord_in_thread": 0, "title": "BRIEF-Glycomimetics Announces Design Of Phase 3 Clinical Trial For GMI-1271", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glycomimetics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Glycomimetics Inc:\n* GLYCOMIMETICS ANNOUNCES DESIGN OF PHASE 3 CLINICAL TRIAL FOR GMI-1271 IN RELAPSED/REFRACTORY AML\n* GLYCOMIMETICS INC - PRIMARY ENDPOINT FOR SINGLE PIVOTAL CLINICAL TRIAL WILL BE OVERALL SURVIVAL\n* GLYCOMIMETICS INC - MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020\n* GLYCOMIMETICS INC - IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T05:16:00.000+02:00", "crawled": "2018-03-06T22:31:54.005+02:00", "highlightTitle": ""}